About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5582314
Allelic
Composition
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (9 available); any Kras mutation (76 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice survive for a median of 84 days after pIpC injection

hematopoietic system
• increase in the number of proliferating splenocytes in pIpC treated mice; most of these proliferating cells are Mac1+/Gr1 lo or Ter119+
• spleens of pIpC-treated moribund mice are massively enlarged (J:87429)
• in pIpC treated mice (J:115071)
• mice treated with pIpC show large numbers of proliferating splenic Ter199+ cells, indicating that erythropoiesis is ineffective (J:87429)
• the erythroid progenitor compartment is massively expanded in the spleen of pIpC treated mice (J:115071)
• pIpC treated mice show normal numbers of early erythroid cells in the bone marrow but a paucity of all the more mature TER119 hi populations, indicating an inefficient transition from TER119- to TER119 hi stages of erythropoiesis (J:115071)
• bone marrow from pIpC treated mice forms abnormally large BFU-E colonies characterized by both erythropoietin-independent growth and hypersensitivity to erythropoietin (J:115071)
• spleen of pIpC treated mice contains increase of immature CD71 hi TER119-/lo cells and large numbers of TER119 hi erythroblasts (J:115071)
• pIpC injected mice develop a myeloproliferative disease with excess monocytes
• bone marrow mononuclear cells from pIpC treated mice form significant numbers of colony-forming unit granulocyte-macrophage (CFU-GM) colonies in the absence of exogenous cytokines while wild-type cells do not
• CFU-GM shows an increased proliferative response without added cytokines (9-fold) or to GM-CSF (19-fold increase) or IL-3 (37-fold increase)
• mice show abundant myeloid cells at various stages of differentiation after pIpC injection
• pups injected with pIpC develop anemia (J:87429)
• however, normal platelet counts are seen in pIpC injected mice (J:87429)
• in pIpC treated mice
• in pIpC treated mice
• in pIpC treated mice
• pups injected with pIpC at 21 days of age develop progressive leukocytosis that is evident 3 weeks after pIpC injection
• mice show an expanded population of Mac-1+, Gr-1 lo cells, indicating an expansion of immature monocytic cells
• in pIpC treated mice

immune system
• increase in the number of proliferating splenocytes in pIpC treated mice; most of these proliferating cells are Mac1+/Gr1 lo or Ter119+
• spleens of pIpC-treated moribund mice are massively enlarged (J:87429)
• in pIpC treated mice (J:115071)
• pIpC injected mice develop a myeloproliferative disease with excess monocytes
• bone marrow mononuclear cells from pIpC treated mice form significant numbers of colony-forming unit granulocyte-macrophage (CFU-GM) colonies in the absence of exogenous cytokines while wild-type cells do not
• CFU-GM shows an increased proliferative response without added cytokines (9-fold) or to GM-CSF (19-fold increase) or IL-3 (37-fold increase)
• mice show abundant myeloid cells at various stages of differentiation after pIpC injection
• pups injected with pIpC at 21 days of age develop progressive leukocytosis that is evident 3 weeks after pIpC injection
• mice show an expanded population of Mac-1+, Gr-1 lo cells, indicating an expansion of immature monocytic cells

liver/biliary system
• pIpC injected mice show moderate hepatomegaly with myeloid infiltration, particularly in periportal areas

cellular
• increase in the number of proliferating splenocytes in pIpC treated mice; most of these proliferating cells are Mac1+/Gr1 lo or Ter119+

homeostasis/metabolism
• serum erythropoietin levels are increased in proportion to anemia in pIpC treated mice

growth/size/body
• pIpC injected mice show moderate hepatomegaly with myeloid infiltration, particularly in periportal areas
• spleens of pIpC-treated moribund mice are massively enlarged (J:87429)
• in pIpC treated mice (J:115071)


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
05/28/2024
MGI 6.13
The Jackson Laboratory